NO20083642L - Dibenzylaminderivater som CETP-inhibitorer - Google Patents
Dibenzylaminderivater som CETP-inhibitorerInfo
- Publication number
- NO20083642L NO20083642L NO20083642A NO20083642A NO20083642L NO 20083642 L NO20083642 L NO 20083642L NO 20083642 A NO20083642 A NO 20083642A NO 20083642 A NO20083642 A NO 20083642A NO 20083642 L NO20083642 L NO 20083642L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- derivatives
- dibenzylamine
- cetp inhibitors
- triglycerides
- Prior art date
Links
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract 2
- 238000008214 LDL Cholesterol Methods 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78148806P | 2006-03-10 | 2006-03-10 | |
| US11/619,299 US8383660B2 (en) | 2006-03-10 | 2007-01-03 | Dibenzyl amine compounds and derivatives |
| PCT/IB2007/000524 WO2007105049A1 (en) | 2006-03-10 | 2007-02-28 | Dibenzyl amine derivatives as cetp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20083642L true NO20083642L (no) | 2008-09-29 |
Family
ID=38085975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20083642A NO20083642L (no) | 2006-03-10 | 2008-08-22 | Dibenzylaminderivater som CETP-inhibitorer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8383660B2 (nl) |
| EP (1) | EP1994015B1 (nl) |
| JP (1) | JP4959731B2 (nl) |
| KR (1) | KR101059274B1 (nl) |
| AP (1) | AP2008004603A0 (nl) |
| AR (1) | AR059802A1 (nl) |
| AU (1) | AU2007226260B2 (nl) |
| BR (1) | BRPI0708753A2 (nl) |
| CA (2) | CA2717242A1 (nl) |
| CR (1) | CR10265A (nl) |
| DK (1) | DK1994015T3 (nl) |
| DO (1) | DOP2007000044A (nl) |
| ES (1) | ES2410859T3 (nl) |
| IL (1) | IL193572A (nl) |
| MA (1) | MA30272B1 (nl) |
| MX (1) | MX2008011045A (nl) |
| NL (1) | NL2000527C2 (nl) |
| NO (1) | NO20083642L (nl) |
| PE (1) | PE20071022A1 (nl) |
| RS (1) | RS20080409A (nl) |
| TW (1) | TW200736235A (nl) |
| UY (1) | UY30197A1 (nl) |
| WO (1) | WO2007105049A1 (nl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2155666A1 (en) * | 2007-05-10 | 2010-02-24 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
| US9394333B2 (en) | 2008-12-02 | 2016-07-19 | Wave Life Sciences Japan | Method for the synthesis of phosphorus atom modified nucleic acids |
| EP2451461A4 (en) | 2009-07-06 | 2013-05-29 | Ontorii Inc | NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF |
| CN102241667B (zh) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 |
| JP2013538215A (ja) | 2010-08-31 | 2013-10-10 | エスエヌユー アールアンドディービー ファウンデーション | ＰＰＡＲδアゴニストの胎児再プログラミング用途 |
| DK2620428T3 (da) * | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
| SG10201605304VA (en) | 2011-07-08 | 2016-08-30 | Novartis Ag | Method of treating atherosclerosis in high triglyceride subjects |
| BR112014001244A2 (pt) | 2011-07-19 | 2017-02-21 | Wave Life Sciences Pte Ltd | métodos para a síntese de ácidos nucléicos funcionalizados |
| MX356830B (es) | 2012-07-13 | 2018-06-15 | Shin Nippon Biomedical Laboratories Ltd | Adyuvante de acido nucleico quiral. |
| SG10201912895PA (en) | 2012-07-13 | 2020-02-27 | Wave Life Sciences Ltd | Chiral control |
| CN104684893B (zh) | 2012-07-13 | 2016-10-26 | 日本波涛生命科学公司 | 不对称辅助基团 |
| CN103351354B (zh) * | 2013-06-09 | 2015-08-12 | 西安近代化学研究所 | 1-甲基-5-氨基四唑合成方法 |
| EP3095460A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
| RU2016133035A (ru) | 2014-01-16 | 2018-02-21 | Уэйв Лайф Сайенсес Лтд. | Хиральный дизайн |
| KR101799793B1 (ko) | 2015-08-17 | 2017-11-21 | 인제대학교 산학협력단 | 신규한 이소나이트라민 화합물 및 이를 포함하는 대사성 질환 예방 또는 치료용 조성물 |
| WO2017030367A1 (ko) * | 2015-08-17 | 2017-02-23 | 인제대학교 산학협력단 | 신규한 이소나이트라민 화합물 및 이를 포함하는 대사성 질환 예방 또는 치료용 조성물 |
| WO2025125486A1 (en) | 2023-12-14 | 2025-06-19 | Syngenta Crop Protection Ag | Process for the preparation of piperidinyl 1,2,4-oxadiazole derivatives |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2161938A (en) | 1934-07-31 | 1939-06-13 | Soc Of Chemical Ind | Imidazolines |
| US2970082A (en) | 1958-10-07 | 1961-01-31 | Walker Lab Inc | Aluminum nicotinate compositions for hypercholesteremia |
| DE1518133B1 (de) | 1961-10-05 | 1970-08-20 | Farmaceutici Italia | Verfahren zur Herstellung eines neuen hypotensiv wirkenden Hendekapeptids |
| US3228943A (en) | 1962-06-11 | 1966-01-11 | Lumilysergol derivatives | |
| US3338899A (en) | 1962-07-09 | 1967-08-29 | Aron Samuel | 3-phenyl-5-amino-1, 2, 4-oxadiazole compounds |
| US3238215A (en) | 1963-10-17 | 1966-03-01 | Sterling Drug Inc | 1-[(3-, 2-, and 1-indolyl)-lower-alkyl-, lower-alkenyl-, and lower-alkynyl]piperidines |
| NL127065C (nl) | 1964-04-22 | |||
| FR1460571A (fr) | 1965-06-10 | 1966-03-04 | Innothera Lab Sa | Composés thiényl acétiques et leur préparation |
| FR6087M (nl) | 1967-01-10 | 1968-06-04 | ||
| US3511836A (en) | 1967-12-13 | 1970-05-12 | Pfizer & Co C | 2,4,6,7-tetra substituted quinazolines |
| NL6903138A (nl) | 1968-03-02 | 1969-09-04 | ||
| GB1218591A (en) | 1968-04-03 | 1971-01-06 | Delalande Sa | Derivatives of n-(3,4,5-trimethoxy cennamoyl) piperazine and their process of preparation |
| CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| FR2092133B1 (nl) | 1970-05-06 | 1974-03-22 | Orsymonde | |
| GB1435139A (en) | 1972-08-17 | 1976-05-12 | Sumitomo Chemical Co | Thiazole derivatives |
| US4146643A (en) | 1973-12-18 | 1979-03-27 | Sandoz Ltd. | Increasing vigilance or treating cerebral insufficiency with substituted vincamines |
| NL175059C (nl) | 1974-02-23 | Boehringer Mannheim Gmbh | Bereiding van bloeddrukverlagende stoffen en van preparaten die ze bevatten. | |
| DE2733747C2 (de) | 1977-07-27 | 1979-09-27 | Hoechst Ag, 6000 Frankfurt | Verfahren zur Herstellung von 2,2 Dichlorhydrazobenzol |
| US4188390A (en) | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
| IT1094076B (it) | 1978-04-18 | 1985-07-26 | Acraf | Cicloalchiltriazoli |
| JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
| GB8501372D0 (en) | 1985-01-18 | 1985-02-20 | Smith Kline French Lab | Chemical compounds |
| US5061798A (en) | 1985-01-18 | 1991-10-29 | Smith Kline & French Laboratories, Ltd. | Benzyl pyridyl and pyridazinyl compounds |
| GB8531071D0 (en) | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| US5284971A (en) | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| ATE159515T1 (de) | 1992-07-21 | 1997-11-15 | Ciba Geigy Ag | Oxamidsäure-derivate als hypocholesterämische mittel |
| DE4435477A1 (de) | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indol- und -azaindol-derivate |
| DK0788496T3 (da) | 1994-10-27 | 2001-06-18 | Janssen Pharmaceutica Nv | Inhibitorer for syntese af apolipoprotein-B |
| US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
| EP0832069B1 (en) | 1995-06-07 | 2003-03-05 | Pfizer Inc. | BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION |
| YU23499A (sh) | 1996-11-27 | 2001-07-10 | Pfizer Inc. | Inhibitorski amidi apo-b-sekrecije/mtp-a |
| JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| KR100575919B1 (ko) | 2001-06-28 | 2006-05-02 | 화이자 프로덕츠 인코포레이티드 | 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜 |
| JP2003221376A (ja) | 2001-11-21 | 2003-08-05 | Japan Tobacco Inc | Ｃｅｔｐ活性阻害剤 |
| US6875780B2 (en) | 2002-04-05 | 2005-04-05 | Warner-Lambert Company | Compounds that modulate PPAR activity and methods for their preparation |
| ATE353870T1 (de) | 2002-08-30 | 2007-03-15 | Japan Tobacco Inc | Dibenzylaminverbindung und deren medizinische verwendung |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
| AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
| DOP2005000123A (es) * | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| AP2007003980A0 (en) | 2004-11-23 | 2007-06-30 | Pfizer Prod Inc | Dibenzylamine compounds and derivatives |
| JP5096927B2 (ja) * | 2004-12-31 | 2012-12-12 | レディ ユーエス セラピューティックス， インコーポレイテッド | Ｃｅｔｐインヒビターとしての新規ベンジルアミン誘導体 |
| EP1942904A4 (en) * | 2005-09-30 | 2009-11-18 | Merck & Co Inc | CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS |
| US7919506B2 (en) * | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
-
2007
- 2007-01-03 US US11/619,299 patent/US8383660B2/en not_active Expired - Fee Related
- 2007-02-28 CA CA2717242A patent/CA2717242A1/en not_active Abandoned
- 2007-02-28 DK DK07705669.5T patent/DK1994015T3/da active
- 2007-02-28 MX MX2008011045A patent/MX2008011045A/es active IP Right Grant
- 2007-02-28 BR BRPI0708753-5A patent/BRPI0708753A2/pt not_active Application Discontinuation
- 2007-02-28 AU AU2007226260A patent/AU2007226260B2/en not_active Ceased
- 2007-02-28 RS RSP-2008/0409A patent/RS20080409A/sr unknown
- 2007-02-28 AP AP2008004603A patent/AP2008004603A0/xx unknown
- 2007-02-28 EP EP07705669.5A patent/EP1994015B1/en active Active
- 2007-02-28 ES ES07705669T patent/ES2410859T3/es active Active
- 2007-02-28 CA CA2645291A patent/CA2645291C/en not_active Expired - Fee Related
- 2007-02-28 WO PCT/IB2007/000524 patent/WO2007105049A1/en not_active Ceased
- 2007-02-28 JP JP2008558923A patent/JP4959731B2/ja not_active Expired - Fee Related
- 2007-02-28 KR KR1020087022081A patent/KR101059274B1/ko not_active Expired - Fee Related
- 2007-03-07 DO DO2007000044A patent/DOP2007000044A/es unknown
- 2007-03-07 NL NL2000527A patent/NL2000527C2/nl not_active IP Right Cessation
- 2007-03-08 UY UY30197A patent/UY30197A1/es not_active Application Discontinuation
- 2007-03-09 PE PE2007000259A patent/PE20071022A1/es not_active Application Discontinuation
- 2007-03-09 AR ARP070100979A patent/AR059802A1/es unknown
- 2007-03-09 TW TW096108178A patent/TW200736235A/zh unknown
-
2008
- 2008-08-20 IL IL193572A patent/IL193572A/en not_active IP Right Cessation
- 2008-08-22 NO NO20083642A patent/NO20083642L/no not_active Application Discontinuation
- 2008-08-29 CR CR10265A patent/CR10265A/es not_active Application Discontinuation
- 2008-09-10 MA MA31226A patent/MA30272B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0708753A2 (pt) | 2011-06-28 |
| JP4959731B2 (ja) | 2012-06-27 |
| KR101059274B1 (ko) | 2011-08-24 |
| CA2645291C (en) | 2011-06-28 |
| AP2008004603A0 (en) | 2008-10-31 |
| IL193572A (en) | 2013-02-28 |
| PE20071022A1 (es) | 2007-10-06 |
| NL2000527C2 (nl) | 2008-02-06 |
| ES2410859T3 (es) | 2013-07-03 |
| TW200736235A (en) | 2007-10-01 |
| UY30197A1 (es) | 2007-10-31 |
| WO2007105049A1 (en) | 2007-09-20 |
| US8383660B2 (en) | 2013-02-26 |
| US20070213314A1 (en) | 2007-09-13 |
| RS20080409A (sr) | 2009-07-15 |
| AR059802A1 (es) | 2008-04-30 |
| DOP2007000044A (es) | 2007-09-15 |
| IL193572A0 (en) | 2009-05-04 |
| CA2645291A1 (en) | 2007-09-20 |
| AU2007226260B2 (en) | 2012-02-09 |
| KR20080093156A (ko) | 2008-10-20 |
| DK1994015T3 (da) | 2013-06-24 |
| EP1994015A1 (en) | 2008-11-26 |
| JP2009529573A (ja) | 2009-08-20 |
| MX2008011045A (es) | 2008-09-08 |
| EP1994015B1 (en) | 2013-04-24 |
| MA30272B1 (fr) | 2009-03-02 |
| AU2007226260A1 (en) | 2007-09-20 |
| CR10265A (es) | 2008-09-23 |
| NL2000527A1 (nl) | 2007-09-11 |
| CA2717242A1 (en) | 2007-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20083642L (no) | Dibenzylaminderivater som CETP-inhibitorer | |
| NO20073025L (no) | Dibenzylaminforbindelser og derivater | |
| NO20084931L (no) | Farmasoytiske sammensetninger | |
| NO20070933L (no) | Indazoler anvendbare i behandling av kardiovaskulaere sykdommer | |
| NO20083568L (no) | Hydantoinforbindelser for behandling av inflammatoriske forstyrrelser | |
| NO20083561L (no) | Forbindelser for behandling av inflammatoriske forstyrrelser | |
| WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| NO20082000L (no) | Pyrimidinamidforbindelser som PGDS-inhibitorer | |
| EA201290389A8 (ru) | Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| UA102574C2 (ru) | 1-фенил-2-пиридинилалкил-спиртовые производные как ингибиторы фосфодиэстеразы | |
| NO20083572L (no) | Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer | |
| NO20084411L (no) | Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI | |
| EA200970090A1 (ru) | Модуляторы метаболизма и лечение связанных с ним расстройств | |
| NO20073849L (no) | Indolderivater for behandling av virale infeksjoner | |
| NO20084418L (no) | Azolopyridin-3-on derivater som inhibitorer av endoteliallipase | |
| NO20084328L (no) | Nye forbindelser | |
| WO2010029302A3 (en) | Compounds for treating viral infections | |
| WO2011056985A3 (en) | Substituted heterocyclic compounds | |
| CO6362026A2 (es) | Derivado de ácido halurónico polisulfatado de bajo peso molecular y un medicamento que lo contiene | |
| NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
| MD20140044A2 (ro) | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare | |
| NO20052921L (no) | Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer | |
| WO2010124121A8 (en) | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor | |
| NO20071510L (no) | 4-Amino-substituerte-2-substituerte-1,2,3,4-tetrahydrokinolinforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |